Core Insights - Fagron has successfully completed the acquisition of Purifarma in Brazil, marking a significant step in its M&A strategy and enhancing its scalable platform for long-term growth [1][2][3] Group 1: Acquisition Details - The acquisition of Purifarma, valued at approximately R$250 million, is expected to provide procurement benefits in Latin America and across Fagron's global operations [2] - Purifarma is recognized as a large-scale Essentials business with a competitive product portfolio and significant volumes, which will allow Fagron to improve its product mix and extend its reach to industrial clients [2][3] Group 2: Strategic Commentary - CEO Rafael Padilla emphasized that the completion of this acquisition strengthens Fagron's position in Brazil and aligns with its disciplined buy-and-build strategy, focusing on scale, procurement, and access to industrial clients [3] - The company aims to remain selective and execution-focused during the integration of Purifarma to build a larger and more efficient platform [3] Group 3: Company Overview - Fagron is a leading global company in pharmaceutical compounding, delivering personalized medicine to various healthcare providers in over 35 countries [5] - The company is headquartered in Nazareth, Belgium, and operates through its Dutch subsidiary, Fagron BV, which is based in Rotterdam [6]

Core Viewpoint - The article highlights the offerings of the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Service Offerings - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio featuring more than 10 small and mid-cap stocks, and live chat for investor engagement [2]. - The service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1]. Group 2: Analyst Background - The author, Terry Chrisomalis, is a private investor with a background in Applied Science, focusing on generating long-term value in the healthcare sector [2]. - The service aims to assist healthcare investors in making informed decisions through comprehensive analysis and news reports [2].

Core Insights - Pfizer Inc. is planning to raise prices on approximately 350 medicines starting January 1, despite broader pricing agreements with the Trump administration aimed at lowering costs for certain treatments [2][4] - The company announced the largest number of list price hikes, affecting around 80 medicines, including notable drugs like Ibrance, Nurtec, and Paxlovid [3][4] - Most price increases are under 10%, with a notable 15% increase for the COVID vaccine Comirnaty, while some lower-priced hospital drugs are seeing increases of more than four times [4] Pricing Strategy - Pfizer's average list price adjustments for innovative medicines and vaccines for 2026 are designed to remain below the overall rate of inflation [4] - The planned price increases for 2026 are higher than the previous year, with over 250 drugs outlined for hikes last year, and this year's median increase is around 4% [5] Company Overview - Pfizer Inc. is a research-driven biopharmaceutical company with global operations, focusing on the discovery, development, manufacturing, and marketing of medicines and vaccines across various therapeutic areas [5]

6 January 2026 | 8:05AM HKT Equity Research BeOne Medicines (ONC/688235.SS): Quick China approval for sonro; eyes on market feedback for differentiation; Buy Sonro approved in China for late-line CLL/MCL: On Jan 5th, China NMPA approved sonrotoclax (BCL2 inhibitor) in R/R CLL/SLL and R/R MCL (post CD20/BTKi treatment), marking the first approval of sonrotoclax across markets (the FDA accepted NDA in R/R MCL in Nov. 2025 with priority review). The China approval took only eight months to complete the NDA rev ...

Market Overview - Major U.S. stock indexes closed higher, with the Dow Jones Industrial Average up 1.2% to 48,977.18, S&P 500 up 0.6% to 6,902.05, and Nasdaq up 0.69% to 23,395.82 [1] Oil Sector - The U.S. military strike in Venezuela led to the ousting of President Nicolás Maduro, sparking renewed interest in the oil sector, particularly for U.S. companies looking to invest in Venezuela's oil industry [1] - Chevron Corp. shares surged 5.1% to close at $163.85, with an intraday high of $165.75, driven by optimism regarding potential gains from geopolitical developments [2][3] - Exxon Mobil Corp. stock gained 2.21%, closing at $125.36, as political changes in Venezuela create new opportunities for the company, focusing on legal recovery and strategic positioning in the oil market [8] Company Highlights - Novo Nordisk A/S shares rose 5.19% to $55.11, with its Wegovy weight loss pill showing an average weight loss of 17% when combined with diet and exercise, compared to 3% for placebo, indicating strong market potential [5] - Zeta Global Holdings Corp. shares increased by 8.84% to close at $21.67, driven by speculation and investor enthusiasm for its AI-powered marketing solutions [6][7]

ExxonMobil's earnings are down over the last few years due to lower oil prices. But even when factoring in those lower earnings, the stock ended 2025 around an all-time high. ExxonMobil still sports a dirt cheap price-to-earnings (P/E) ratio of 17.6. ExxonMobil's efficiency improvements and cost reductions position it well to generate cash flow at higher oil prices, which could also pique investor interest and justify a higher P/E ratio for ExxonMobil -- potentially pushing it over the $1 trillion mark in t ...

Table of Contents As filed with the Securities and Exchange Commission on January 5, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Graphic METAVIA INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (Primary Standard Industrial (IRS Employer incorporation or organization) Classification Code Number) Identification Number) Delaware 2834 47-2389984 545 C ...

Core Viewpoint - Abbott is set to announce its fourth-quarter 2025 financial results on January 22, 2026, before market opening, followed by a live webcast of the earnings conference call [1] Group 1: Financial Announcement - The financial results announcement will occur on January 22, 2026, before the market opens [1] - A live webcast of the earnings conference call will take place at 8 a.m. Central time (9 a.m. Eastern) [1] - The archived edition of the call will be available later that same day [1] Group 2: Company Overview - Abbott is a global healthcare leader with a focus on helping people live fully at all stages of life [2] - The company's portfolio includes technologies in diagnostics, medical devices, nutritionals, and branded generic medicines [2] - Abbott employs 114,000 colleagues and serves customers in over 160 countries [2]

TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version o ...

Key Takeaways U.S. military action of capturing Venezuela's leadership triggers a major geopolitical shock globally.Venezuela's oil impact is limited, as it produces about 1% of global supply and Chevron's exposure is small.Defense, cybersecurity tech & healthcare stocks stand to benefit from higher security spending and stability.The year 2026 has started in an unusually volatile way. The United States’ recent military action to capture Venezuela, home to the world’s largest proven oil reserves, has come a ...